Verve Therapeutics Inc (NASDAQ:VERV) price on Wednesday, February 05, rose 7.07% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $8.63.
A look at the stock’s price movement, the close in the last trading session was $8.06, moving within a range at $8.155 and $8.7699. The beta value (5-Year monthly) was 1.76. Turning to its 52-week performance, $19.34 and $4.30 were the 52-week high and 52-week low respectively. Overall, VERV moved 38.30% over the past month.
Verve Therapeutics Inc’s market cap currently stands at around $730.65 million, with investors looking forward to this quarter’s earnings report slated for in March.
The average forecast suggests down to a -17.60% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 23.85M, representing a 102.87% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that VERV is a 100% Buy. On the other hand, the stock is on average a 100% Buy as suggested by medium term indicators while long term indicators are putting the stock in 100% Buy category.
8 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 2 analyst(s) rate the stock as a Hold, 5 recommend VERV as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 1 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
VERV’s current price about 24.49% and 36.35% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 68.46, while 7-day volatility ratio is 7.99% and 9.55% in the 30-day chart. Further, Verve Therapeutics Inc (VERV) has a beta value of 1.74, and an average true range (ATR) of 0.65. Analysts have given the company’s stock an average 52-week price target of $14, forecast between a low of $14 and high of $14. Looking at the price targets, the low is -62.22% off current price level while to achieve the yearly target high, price needs to move -62.22%. Nonetheless, investors will most likely welcome a -62.22% jump to $14 which is the analysts’ median price.
If we refocus on Verve Therapeutics Inc (NASDAQ:VERV), historical trading data shows that trading volumes averaged 2.04 over the past 10 days and 1.71 million over the past 3 months. The company’s latest data on shares outstanding shows there are 84.64 million shares.
The 25.47% of Verve Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 74.99% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 14.79 million on 2025-01-15, giving us a short ratio of 10.17. The data shows that as of 2025-01-15 short interest in Verve Therapeutics Inc (VERV) stood at 2085.0 of shares outstanding, with shares short falling to 15.97 million registered in 2024-12-13. Current price change has pushed the stock 53.01% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the VERV stock continues to rise going into the next quarter.
